微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2017, Vol. 9 ›› Issue (3): 167-171.doi: 10.3969/j.issn.1674-5671.2017.03.01

• 基础研究 •    下一篇

TMT定量蛋白质组学方法筛选鼻咽癌复发相关表达蛋白

  

  1. 广西医科大学附属肿瘤医院放疗科；广西医科大学研究生院；区域性高发肿瘤早期防治研究教育部重点实验室
  • 出版日期:2017-06-25 发布日期:2017-08-02
  • 基金资助:

    广西医疗卫生重点科研课题资助项目（重2012091）；区域性高发肿瘤早期防治研究教育部重点实验室资助项目（GK2014-ZZ12，GK2015-ZZ05）

Identification of novel serum biomarkers for recurrent nasopharyngeal carcinoma using TMT-based quantitative proteomic analysis

  • Online:2017-06-25 Published:2017-08-02
  • Contact: 曲颂 daisyqs2002@163.com

PDF (PC)

631

赞

被引次数

1

摘要：

目的 筛选鼻咽癌复发与正常复查随访患者血清差异表达蛋白，寻找鼻咽癌复发诊断的标志物。方法 采集复发20例和正常复查随访20例鼻咽癌患者血清，采用TMT联合二维质谱筛选差异蛋白。进一步收集新标本并采用酶联免疫吸附法（enzyme-linked immunosorbent assay，ELISA）验证差异蛋白，其中复发40例和正常复查随访41例。结果 血清中共鉴定出635个蛋白，其中可定量蛋白为413个。两次生物学重复实验中，复发组均表现下调的蛋白有41个，均表现为上调的蛋白有18个。血清ELISA验证结果发现，复发组A2M蛋白浓度较正常复查随访组低（Z=-3.177，P=0.001）。复发组40例患者中可测出A2M蛋白浓度23例，正常复查随访组41例患者中可测出A2M蛋白浓度30例，Spearman相关分析结果显示，可测复发组和可测正常复查随访组患者A2M蛋白浓度与肿瘤分期（r=-0.024，P=0.866）、年龄（r=-0.087，P=0.534）均无相关性，两组患者年龄、性别及肿瘤分期等差异无统计学意义（P＞0.05）。结论 A2M蛋白可能是鼻咽癌复发诊断的潜在标志物。

关键词: 鼻咽肿瘤, 鼻咽癌复发, TMT, 蛋白质组学, A2M, 生物标志物

Abstract:

Objective To identify proteins differentially expressed between recurrent nasopharyngeal carcinoma（NPC） and non-recurrent NPC. Method Serum was collected from 20 patients with recurrent NPC and 20 patients with non-recurrent NPC. We used tandem mass tag labeling and high performance liquid chromatography fractionation，followed by liquid chromatography-tandem mass spectrometry to identify differentially expressed proteins. Candidate proteins were confirmed by ELISA in a separate set of serum samples comprising 40 patients with recurrent NPC and 41 with non-recurrent NPC. Results A total of 635 protein groups were identified in human serum，and expression levels of 413 proteins were quantified. In two independent tests with different subgroups of patients，41 proteins were found to be down-regulated and 18 to be up-regulated in recurrent disease. ELISA confirmed that A2M was down-regulated in 23 patients with recurrent disease compared to 30 with non-recurrent disease. （Other patients had A2M levels below the detection threshold of the ELISA）. Spearman analysis showed that A2M concentration did not correlate with clinical stage （r =-0.024，P=0.866） or age（r =-0.087，P=0.534）. Conclusion A2M expression may protect against risk of NPC recurrence and so may be a useful prognostic marker.

Key words: Nasopharyngeal neoplasms, Recurrent nasopharyngeal carcinoma, TMT, Proteomics, A2M, Biomarker